Clinical implications of pharmacogenomics for tardive dyskinesia
Pharmacogenomics J
.
2004;4(2):77-87.
doi: 10.1038/sj.tpj.6500233.
Authors
D J Müller
1
,
T Shinkai
,
V De Luca
,
J L Kennedy
Affiliation
1
Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, ON, Canada.
PMID:
15042144
DOI:
10.1038/sj.tpj.6500233
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Review
MeSH terms
Animals
Clinical Trials as Topic / trends*
Dyskinesia, Drug-Induced / genetics*
Dyskinesia, Drug-Induced / metabolism
Humans
Pharmacogenetics / trends*